Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities (2022 - 2025)

Stoke Therapeutics has reported Other Non-Current Liabilities over the past 4 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.1 million for Q4 2025, down 53.95% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (down 53.95% YoY), and the annual figure for FY2025 was $1.1 million, down 53.95%.
  • Other Non-Current Liabilities for Q4 2025 was $1.1 million at Stoke Therapeutics, down from $1.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for STOK hit a ceiling of $4.9 million in Q4 2023 and a floor of $959000.0 in Q3 2023.
  • Median Other Non-Current Liabilities over the past 4 years was $2.7 million (2022), compared with a mean of $2.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 73.43% in 2023 and later skyrocketed 218.04% in 2024.
  • Stoke Therapeutics' Other Non-Current Liabilities stood at $3.0 million in 2022, then soared by 64.56% to $4.9 million in 2023, then crashed by 49.26% to $2.5 million in 2024, then plummeted by 53.95% to $1.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $1.1 million (Q4 2025), $1.9 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.